“…The original choice of PGA as a biomaterial was based on: (i) longterm experience and use as a medical device for, e.g., suture material, osteofixation, and cartilage repair [2,7,25,26]; (ii) its character as a non-natural, synthetic product, avoiding problems such as rejection for religious reasons and virus or prion contamination but allowing easy melting, processing, or spinning for manufacturing [7]; (iii) its complete resorption in vivo within 3 months [27], following hydrolytic breakdown into natural degradation products [7]. In this context, potential induction of inflammation and osteolysis by breakdown products of such synthetic biopolymers may be more of a problem for bulk screw and osteofixation biomaterials than for scaffolds and sutures [1,2,7,25,28]. Additionally, the relative suitability of PGA/PLGA versus alginate, hyaluronic acid, or chitosan, which are similar to and/or interact with local glycosaminoglycans for cartilage regeneration [1], should be assessed by 'contemplating both potential advantages and disadvantages of each technique' [7] and by optimizing the match between 'the final product properties .…”